Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norquetiapine is the major active metabolite of quetiapine, an atypical antipsychotic. It exhibits a distinctive pharmacological profile and is thought to contribute to the antidepressant and anxiolytic effects of quetiapine treatment. Mechanistically, norquetiapine acts as a potent inhibitor of the noradrenaline transporter (NET), a partial agonist at 5-HT1A (serotonin) receptors, and an antagonist at presynaptic alpha-2 adrenergic, 5-HT2C, and 5-HT7 receptors. It is also an antagonist at histamine H1, alpha-1 adrenergic, and muscarinic receptors. This broad spectrum of receptor affinities confers norquetiapine an antidepressant and anxiolytic pharmacological profile that is distinct from its parent compound[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norquetiapine.